Cardiovascular Comorbidity in Rheumatic Diseases: A Focus on Heart Failure

Heart Failure Clinics

Volumn 10, Issue 2, 2014, Pages 339-352

  Wright, Kerry ^a   Crowson, Cynthia S ^a   Gabriel, Sherine E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cardiovascular disease; Heart failure; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

BIOLOGICAL PRODUCT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR;

ADAPTIVE IMMUNITY; AGE; ANKYLOSING SPONDYLITIS; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CLINICAL FEATURE; COMORBIDITY; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DIASTOLIC DYSFUNCTION; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE DURATION; DYSPNEA; ECHOCARDIOGRAPHY; EPIDEMIOLOGICAL DATA; ERYTHROCYTE SEDIMENTATION RATE; FRAMINGHAM RISK SCORE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INNATE IMMUNITY; ISCHEMIC HEART DISEASE; NONHUMAN; OBESITY; PAROXYSMAL DYSPNEA; PATHOPHYSIOLOGY; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; COMPLICATION; RHEUMATIC DISEASES;

HEART FAILURE; HUMANS; PROGNOSIS; RHEUMATIC DISEASES; RISK FACTORS;

EID: 84896398269     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2013.10.003     Document Type: Review

References (128)

1. Gonzalez A., Maradit Kremers H., Crowson C.S., et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007, 56(11):3583-3587.
2. Spector T.D. Rheumatoid arthritis. Rheum Dis Clin North Am 1990, 16(3):513-537.
3. Crowson C.S., Matteson E.L., Myasoedova E., et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011, 63(3):633-639.
4. Gabriel S.E., Crowson C.S., Kremers H.M., et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003, 48(1):54-58.
5. Gabriel S.E. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 2008, 121(10 Suppl 1):S9-S14.
6. Avina-Zubieta J.A., Choi H.K., Sadatsafavi M., et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008, 59(12):1690-1697.
7. Nicola P.J., Crowson C.S., Maradit-Kremers H., et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 2006, 54(1):60-67.
8. Watson D.J., Rhodes T., Guess H.A. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in theUK General Practice Research Database. JRheumatol 2003, 30(6):1196-1202.
9. Wolfe F., Freundlich B., Straus W.L. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. JRheumatol 2003, 30(1):36-40.
10. Maradit-Kremers H., Crowson C.S., Nicola P.J., et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005, 52(2):402-411.
11. Solomon D.H., Karlson E.W., Rimm E.B., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107(9):1303-1307.
12. Van Doornum S., McColl G., Wicks I.P. Accelerated atherosclerosis: an extra-articular feature of rheumatoid arthritis?. Arthritis Rheum 2002, 46(4):862-873.
13. Rho Y.H., Chung C.P., Oeser A., et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009, 61(11):1580-1585.
14. He J., Ogden L.G., Bazzano L.A., et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001, 161(7):996-1002.
15. Nicola P.J., Maradit-Kremers H., Roger V.L., et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005, 52(2):412-420.
16. Davis J.M., Roger V.L., Crowson C.S., et al. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum 2008, 58(9):2603-2611.
17. Wolfe F., Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004, 116(5):305-311.
18. Crowson C.S., Nicola P.J., Kremers H.M., et al. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?. Arthritis Rheum 2005, 52(10):3039-3044.
19. Alpaslan M., Onrat E., Evcik D. Doppler echocardiographic evaluation of ventricular function in patients with rheumatoid arthritis. Clin Rheumatol 2003, 22(2):84-88.
20. Di Franco M., Paradiso M., Mammarella A., et al. Diastolic function abnormalities in rheumatoid arthritis. Evaluation By echo Doppler transmitral flow and pulmonary venous flow: relation with duration of disease. Ann Rheum Dis 2000, 59(3):227-229.
21. Myasoedova E., Crowson C.S., Nicola P.J., et al. The influence of rheumatoid arthritis disease characteristics on heart failure. JRheumatol 2011, 38(8):1601-1606.
22. Kane G.C., Karon B.L., Mahoney D.W., et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 2011, 306(8):856-863.
23. Lam C.S., Lyass A., Kraigher-Krainer E., et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation 2011, 124(1):24-30.
24. Redfield M.M., Jacobsen S.J., Burnett J.C., et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289(2):194-202.
25. Aurigemma G.P., Gottdiener J.S., Shemanski L., et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. JAm Coll Cardiol 2001, 37(4):1042-1048.
26. Bella J.N., Palmieri V., Roman M.J., et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation 2002, 105(16):1928-1933.
27. Solomon D.H., Curhan G.C., Rimm E.B., et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004, 50(11):3444-3449.
28. Crowson C.S., Therneau T.M., Davis J.M., et al. Accelerated aging influences cardiovascular disease risk in rheumatoid arthritis. Arthritis Rheum 2013, 65:2562-2566.
29. Gonzalez A., Maradit Kremers H., Crowson C.S., et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?. Ann Rheum Dis 2008, 67(1):64-69.
30. Boyer J.F., Gourraud P.A., Cantagrel A., et al. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 2011, 78(2):179-183.
31. Escalante A., Haas R.W., del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005, 165(14):1624-1629.
32. Myasoedova E., Crowson C.S., Kremers H.M., et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011, 70(3):482-487.
33. Choy E., Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009, 68(4):460-469.
34. Steiner G., Urowitz M.B. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 2009, 38(5):372-381.
35. Lazarevic M.B., Vitic J., Mladenovic V., et al. Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum 1992, 22(3):172-178.
36. Myasoedova E., Gabriel S.E., Green A.B., et al. The impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis (RA) vs. non-RA subjects: results from a population-based study. Arthritis Care Res (Hoboken) 2013, 65:1592-1599.
37. Scott I.C., Ibrahim F., Johnson D., et al. Current limitations in the management of cardiovascular risk in rheumatoid arthritis. Clin Exp Rheumatol 2012, 30(2):228-232.
38. Toms T.E., Panoulas V.F., Douglas K.M., et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. Ann Rheum Dis 2010, 69(4):683-688.
39. Panoulas V.F., Douglas K.M., Milionis H.J., et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007, 46(9):1477-1482.
40. van Halm V.P., Peters M.J., Voskuyl A.E., et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009, 68(9):1395-1400.
41. Peters M.J., van Halm V.P., Voskuyl A.E., et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009, 61(11):1571-1579.
42. Peters M.J., Symmons D.P., McCarey D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69(2):325-331.
43. Solomon D.H., Peters M.J., Nurmohamed M.T., et al. Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis. Arthritis Rheum 2013, 65(7):1675-1683.
44. Van Doornum S., Brand C., King B., et al. Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54(7):2061-2068.
45. Sodergren A., Stegmayr B., Lundberg V., et al. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis 2007, 66(2):263-266.
46. McCoy S.S., Crowson C.S., Maradit-Kremers H., et al. Long-term outcomes and treatment after myocardial infarction in patients with rheumatoid arthritis. JRheumatol 2013, 40(5):605-610.
47. Van Doornum S., Brand C., Sundararajan V., et al. Rheumatoid arthritis patients receive less frequent acute reperfusion and secondary prevention therapy after myocardial infarction compared with the general population. Arthritis Res Ther 2010, 12(5):R183.
48. Francis M.L., Varghese J.J., Mathew J.M., et al. Outcomes in patients with rheumatoid arthritis and myocardial infarction. Am J Med 2010, 123(10):922-928.
49. Monaco C., Terrando N., Midwood K.S. Toll-like receptor signaling: common pathways that drive cardiovascular disease and rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011, 63(4):500-511.
50. Bjorkbacka H., Lavant E.H., Fredrikson G.N., et al. Weak associations between human leucocyte antigen genotype and acute myocardial infarction. JIntern Med 2010, 268(1):50-58.
51. Palikhe A., Sinisalo J., Seppanen M., et al. Human MHC region harbors both susceptibility and protective haplotypes for coronary artery disease. Tissue Antigens 2007, 69(1):47-55.
52. Paakkanen R., Lokki M.L., Seppanen M., et al. Proinflammatory HLA-DRB1*01-haplotype predisposes to ST-elevation myocardial infarction. Atherosclerosis 2012, 221(2):461-466.
53. Martens P.B., Goronzy J.J., Schaid D., et al. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum 1997, 40(6):1106-1114.
54. Gerli R., Schillaci G., Giordano A., et al. CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004, 109(22):2744-2748.
55. Nakajima T., Schulte S., Warrington K.J., et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 2002, 105(5):570-575.
56. Masiha S., Sundstrom J., Lind L. Inflammatory markers are associated with left ventricular hypertrophy and diastolic dysfunction in a population-based sample of elderly men and women. JHum Hypertens 2013, 27(1):13-17.
57. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108(19):2317-2322.
58. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003, 107(11):1486-1491.
59. Deswal A., Petersen N.J., Feldman A.M., et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001, 103(16):2055-2059.
60. Liang K.P., Myasoedova E., Crowson C.S., et al. Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Ann Rheum Dis 2010, 69(9):1665-1670.
61. Maradit-Kremers H., Nicola P.J., Crowson C.S., et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005, 52(3):722-732.
62. Maradit-Kremers H., Nicola P.J., Crowson C.S., et al. Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66(1):76-80.
63. Rudominer R.L., Roman M.J., Devereux R.B., et al. Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum 2009, 60(1):22-29.
64. Bluemke D.A., Kronmal R.A., Lima J.A., et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. JAm Coll Cardiol 2008, 52(25):2148-2155.
65. Myasoedova E., Davis J.M., Crowson C.S., et al. Brief report: rheumatoid arthritis is associated with left ventricular concentric remodeling: results of a population-based cross-sectional study. Arthritis Rheum 2013, 65(7):1713-1718.
66. Amundsen B.H., Helle-Valle T., Edvardsen T., et al. Noninvasive myocardial strain measurement by speckle tracking echocardiography: validation against sonomicrometry and tagged magnetic resonance imaging. JAm Coll Cardiol 2006, 47(4):789-793.
67. Sitia S., Tomasoni L., Cicala S., et al. Detection of preclinical impairment of myocardial function in rheumatoid arthritis patients with short disease duration by speckle tracking echocardiography. Int J Cardiol 2012, 160(1):8-14.
68. Fine N., Crowson C.S., Lin G. Evaluation of myocardial function in patients with rheumatoid arthritis using strain imaging by speckle-tracking echocardiography. Ann Rheum Dis 2013, [Epub ahead of print].
69. Tomasson G., Aspelund T., Jonsson T., et al. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis 2010, 69(9):1649-1654.
70. Liang K.P., Kremers H.M., Crowson C.S., et al. Autoantibodies and the risk of cardiovascular events. JRheumatol 2009, 36(11):2462-2469.
71. Kerola A.M., Kauppi M.J., Kerola T., et al. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?. Ann Rheum Dis 2012, 71(10):1606-1615.
72. Holmqvist M.E., Wedren S., Jacobsson L.T., et al. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum 2009, 60(10):2861-2869.
73. Holmqvist M.E., Wedren S., Jacobsson L.T., et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. JIntern Med 2010, 268(6):578-585.
74. Yavasoglu I., Senturk T., Onbasili A. Diastolic dysfunction in rheumatoid arthritis and duration of disease. Rheumatol Int 2008, 29(1):113-114.
75. Levendoglu F., Temizhan A., Ugurlu H., et al. Ventricular function abnormalities in active rheumatoid arthritis: a Doppler echocardiographic study. Rheumatol Int 2004, 24(3):141-146.
76. Maisel A.S., Koon J., Krishnaswamy P., et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001, 141(3):367-374.
77. Crowson C.S., Myasoedova E., Davis J.M., et al. Use of B-type natriuretic peptide as a screening tool for left ventricular diastolic dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease. Arthritis Care Res (Hoboken) 2011, 63(5):729-734.
78. Provan S.A., Angel K., Odegard S., et al. The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study. Arthritis Res Ther 2008, 10(3):R70.
79. Crowson C.S., Matteson E.L., Roger V.L., et al. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 2012, 110(3):420-424.
80. Souverein P.C., Berard A., Van Staa T.P., et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004, 90(8):859-865.
81. Wei L., MacDonald T.M., Walker B.R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004, 141(10):764-770.
82. Davis J.M., Maradit Kremers H., Crowson C.S., et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007, 56(3):820-830.
83. Crowson C.S., Roger V.L., Matteson E.L., et al. Hospitalizations following heart failure diagnosis in rheumatoid arthritis. Arthritis Rheum 2010, 62(Suppl 10):67.
84. Antman E.M., Bennett J.S., Daugherty A., et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007, 115(12):1634-1642.
85. Aw T.J., Haas S.J., Liew D., et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005, 165(5):490-496.
86. Bernatsky S., Hudson M., Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005, 44(5):677-680.
87. Choi H.K., Hernan M.A., Seeger J.D., et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359(9313):1173-1177.
88. Westlake S.L., Colebatch A.N., Baird J., et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010, 49(2):295-307.
89. Micha R., Imamura F., Wyler von Ballmoos M., et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011, 108(9):1362-1370.
90. Suissa S., Bernatsky S., Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006, 55(4):531-536.
91. Naranjo A., Sokka T., Descalzo M.A., et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008, 10(2):R30.
92. Anker S.D., Coats A.J. How to RECOVER from RENAISSANCE? The significance of the results ofRECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002, 86(2-3):123-130.
93. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109(13):1594-1602.
94. Coletta A.P., Clark A.L., Banarjee P., et al. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail 2002, 4(4):559-561.
95. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107(25):3133-3140.
96. Listing J., Strangfeld A., Kekow J., et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. Arthritis Rheum 2008, 58(3):667-677.
97. Gabriel S.E. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?. Arthritis Rheum 2008, 58(3):637-640.
98. Singh J.A., Furst D.E., Bharat A., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64(5):625-639.
99. Bulkley B.H., Roberts W.C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36necropsypatients. Am J Med 1975, 58(2):243-264.
100. Haider Y.S., Roberts W.C. Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am J Med 1981, 70(4):775-781.
101. Hak A.E., Karlson E.W., Feskanich D., et al. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum 2009, 61(10):1396-1402.
102. Jonsson H., Nived O., Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989, 68(3):141-150.
103. Asanuma Y., Oeser A., Shintani A.K., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. NEngl J Med 2003, 349(25):2407-2415.
104. Roman M.J., Shanker B.A., Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. NEngl J Med 2003, 349(25):2399-2406.
105. Manzi S., Meilahn E.N., Rairie J.E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145(5):408-415.
106. Pons-Estel G.J., Gonzalez L.A., Zhang J., et al. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology (Oxford) 2009, 48(7):817-822.
107. Knight J.S., Kaplan M.J. Cardiovascular disease in lupus: insights and updates. Curr Opin Rheumatol 2013, 25:597-605.
108. Thacker S.G., Zhao W., Smith C.K., et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum 2012, 64(9):2975-2985.
109. Ward M.M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999, 42(2):338-346.
110. Buss S.J., Wolf D., Korosoglou G., et al. Myocardial left ventricular dysfunction in patients with systemic lupus erythematosus: new insights from tissue Doppler and strain imaging. JRheumatol 2010, 37(1):79-86.
111. Pieretti J., Roman M.J., Devereux R.B., et al. Systemic lupus erythematosus predicts increased left ventricular mass. Circulation 2007, 116(4):419-426.
112. Bruce I.N., Urowitz M.B., Gladman D.D., et al. Riskfactors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003, 48(11):3159-3167.
113. Petri M., Spence D., Bone L.R., et al. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992, 71(5):291-302.
114. Rahman P., Urowitz M.B., Gladman D.D., et al. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. JRheumatol 1999, 26(11):2363-2368.
115. Bruce I.N., Gladman D.D., Urowitz M.B. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000, 26(2):257-278.
116. Esdaile J.M., Abrahamowicz M., Grodzicky T., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44(10):2331-2337.
117. Frostegard J. Rheumatic diseases: insights into inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30(5):892-893.
118. Bremander A., Petersson I.F., Bergman S., et al. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2011, 63(4):550-556.
119. Szabo S.M., Levy A.R., Rao S.R., et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 2011, 63(11):3294-3304.
120. McCarey D., Sturrock R.D. Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis. Clin Exp Rheumatol 2009, 27(4 Suppl 55):S124-S126.
121. Han C., Robinson D.W., Hackett M.V., et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. JRheumatol 2006, 33(11):2167-2172.
122. Prodanovich S., Kirsner R.S., Kravetz J.D., et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009, 145(6):700-703.
123. Kaye J.A., Li L., Jick S.S. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008, 159(4):895-902.
124. Gelfand J.M., Neimann A.L., Shin D.B., et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006, 296(14):1735-1741.
125. Tobin A.M., Veale D.J., Fitzgerald O., et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. JRheumatol 2010, 37(7):1386-1394.
126. Kimhi O., Caspi D., Bornstein N.M., et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007, 36(4):203-209.
127. Jamnitski A., Symmons D., Peters M.J., et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013, 72(2):211-216.
128. Gladman D.D., Ang M., Su L., et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009, 68(7):1131-1135.